Table 3.
Survival analyses for prognosticators of overall survival in epithelioid glioblastoma patients
| Parameter | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% Confidence Interval | P | HR | 95% Confidence Interval | P | |
| Age | 1.008 | 0.985–1.032 | 0.513 | |||
| Sex | 1.863 | 0.911–3.809 | 0.288 | |||
| Tumor dissemination | 1.984 | 1.003–3.923 | 0.049 | 3.648 | 1.507–8.975 | 0.004 |
| Extent of resection | ||||||
| GTR | 1 (Reference) | 1(Reference) | ||||
| STR | 2.861 | 1.113–7.352 | 0.029 | 0.439 | 0.107–1.802 | 0.253 |
| PR | 1.206 | 0.451–3.224 | 0.708 | 0.517 | 0.163–1.641 | 0.263 |
| Tumor stroke | 0.919 | 0.397–2.129 | 0.844 | |||
| Pre-operative KPS | 1.015 | 0.991–1.039 | 0.221 | |||
| Radiotherapy | 0.200 | 0.081–0.495 | < 0.001 | 0.223 | 0.066–0.781 | 0.019 |
| Adjuvant oral TMZ | 0.408 | 0.192–0.868 | 0.020 | 0.254 | 0.093–0.689 | 0.007 |
| Ki-67 | 0.583 | 0.247–1.378 | 0.219 | |||
| BRAF inhibitor | 0.842 | 0.294–2.411 | 0.749 | |||
| BRAF-V600E | 1.034 | 0.502–2.130 | 0.927 | |||
| MGMT | 1.459 | 0.716–2.973 | 0.298 | |||
| ATRX | 1.504 | 0.555–4.075 | 0.423 | |||
| GFAP | 0.582 | 0.222–1.526 | 0.271 | |||
| Olig-2 | 0.403 | 0.119–1.368 | 0.245 | |||
| P53 | 1.027 | 0.488–2.160 | 0.944 | |||
GTR Gross Total Resection, STR Subtotal Resection, PR Partial Resection, KPS Karnofsky Performance Scale, TMZ temozolomide, MGMT Methylguanine DNA Methyltransferase, GFAP Glial Fibrillary Acidic Protein, ATRX X-linked alpha-thalassemia mental retardation syndrome, Olig-2 Oligodendrocyte Transcription Factor 2